One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiac455 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Heiko Ilchmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harrison Clinical Research Deutschland, GmbH, Munich, Germany. Hauptthemen laut MEDLINE: Smallpox, Vaccinia, Smallpox Vaccine. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Bavarian Nordic.
Abstract (Originalsprache)
Background
Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is approved for smallpox and monkeypox prevention, immunological persistence and booster effects remain undescribed.
Methods
Participants naive to smallpox vaccination were randomized to 1 dose MVA-BN (1×MVA, n = 181), 2 doses MVA-BN (2×MVA, n = 183), or placebo (n = 181). Participants with previous smallpox vaccination received 1 MVA-BN booster (HSPX, n = 200). Subsets of the formerly naive groups (approximately 75 each) received an MVA-BN booster 2 years later.
Results
Neutralizing antibody (nAb) geometric mean titers (GMTs) increased from 1.1 (baseline, both naive groups) to 7.2 and 7.5 (week 4, 1×MVA and 2×MVA, respectively), and further to 45.6 (week 6, 2×MVA after second vaccination). In HSPX, nAb GMT rapidly increased from 21.6 (baseline) to 175.1 (week 2). At 2 years, GMTs for 1×MVA, 2×MVA, and HSPX were 1.1, 1.3, and 10.3, respectively. After boosting in the previously naive groups, nAb GMTs increased rapidly in 2 weeks to 80.7 (1×MVA) and 125.3 (2×MVA), higher than after primary vaccination and comparable to boosted HSPX subjects. Six months after boosting, GMTs were 25.6 (1×MVA) and 49.3 (2×MVA). No safety concerns were identified.
Conclusions
Anamnestic responses to boosting without sustained high nAb titers support presence of durable immunological memory following primary MVA-BN immunization. Clinical Trials Registration. NCT00316524 and NCT00686582.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harrison Clinical Research Deutschland, GmbH, Munich, Germany.
- Bavarian Nordic, GmbH, Martinsried, Germany.
- Bavarian Nordic, Inc, Durham, North Carolina, USA.
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.
- Public Health Vaccines, LLC, Cambridge, Massachusetts, USA.
- Bavarian Nordic, AG, Zug, Switzerland.
ORCID-Profile: Liddy Chen
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Bavarian Nordic
Zitieren
APA
Ilchmann, H., Samy, N., Reichhardt, D., Schmidt, D., Powell, J. D., Meyer, T. P. H., Silbernagl, G., Nichols, R., Weidenthaler, H., De Moerlooze, L., Chen, L., & Chaplin, P. (2023). One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac455
Vancouver
Ilchmann H, Samy N, Reichhardt D, Schmidt D, Powell JD, Meyer TPH, et al. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac455
BibTeX
@article{Ilchmann2023,
author = {Ilchmann, Heiko and Samy, Nathaly and Reichhardt, Daniela and Schmidt, Darja and Powell, Jacqueline D and Meyer, Thomas P H and Silbernagl, Günter and Nichols, Rick and Weidenthaler, Heinz and De Moerlooze, Laurence and Chen, Liddy and Chaplin, Paul},
title = {One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiac455}
}
EUVIMED